Literature DB >> 10944446

Baculoviral display of functional scFv and synthetic IgG-binding domains.

D G Mottershead1, K Alfthan, K Ojala, K Takkinen, C Oker-Blom.   

Abstract

Viral vectors displaying specific ligand binding moities such as scFv fragments or intact antibodies hold promise for the development of targeted gene therapy vectors. In this report we describe baculoviral vectors displaying either functional scFv fragments or the synthetic Z/ZZ IgG binding domain derived from protein A. Display on the baculovirus surface was achieved via fusion of the scFv fragment or Z/ZZ domain to the N-terminus of gp64, the major envelope protein of the Autographa californica nuclear polyhedrosis virus, AcNPV. As examples of scFv fragments we have used a murine scFv specific for the hapten 2-phenyloxazolone and a human scFv specific for carcinoembryonic antigen. In principle, the Z/ZZ IgG binding domain displaying baculoviruses could be targeted to specific cell types via the binding of an appropriate antibody. We envisage applications for scFv and Z/ZZ domain displaying baculoviral vectors in the gene therapy field. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10944446     DOI: 10.1006/bbrc.2000.3264

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Baculovirus entry into human hepatoma cells.

Authors:  Heli Matilainen; Johanna Rinne; Leona Gilbert; Varpu Marjomäki; Hilkka Reunanen; Christian Oker-Blom
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Baculovirus display of functional antibody Fab fragments.

Authors:  Shinya Takada; Takafumi Ogawa; Kazusa Matsui; Tasuku Suzuki; Tomohisa Katsuda; Hideki Yamaji
Journal:  Cytotechnology       Date:  2015-04-24       Impact factor: 2.058

3.  Cloning, expression, purification, and characterization of LC-1 ScFv with GFP tag.

Authors:  Min Lu; Xing-guo Gong; Hong Yu; Jian-yong Li
Journal:  J Zhejiang Univ Sci B       Date:  2005-08       Impact factor: 3.066

4.  Engineering the PP7 Virus Capsid as a Peptide Display Platform.

Authors:  Liangjun Zhao; Mykhailo Kopylov; Clinton S Potter; Bridget Carragher; M G Finn
Journal:  ACS Nano       Date:  2019-03-26       Impact factor: 15.881

5.  Display of heterologous proteins on gp64null baculovirus virions and enhanced budding mediated by a vesicular stomatitis virus G-stem construct.

Authors:  Jian Zhou; Gary W Blissard
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

6.  The baculovirus GP64 protein mediates highly stable infectivity of a human respiratory syncytial virus lacking its homologous transmembrane glycoproteins.

Authors:  A G P Oomens; Gail W Wertz
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  Baculovirus display of single chain antibody (scFv) using a novel signal peptide.

Authors:  Kuntida Kitidee; Sawitree Nangola; Gaëlle Gonzalez; Pierre Boulanger; Chatchai Tayapiwatana; Saw-See Hong
Journal:  BMC Biotechnol       Date:  2010-11-19       Impact factor: 2.563

8.  Purification of functional baculovirus particles from silkworm larval hemolymph and their use as nanoparticles for the detection of human prorenin receptor (PRR) binding.

Authors:  Tatsuya Kato; Fumiaki Suzuki; Enoch Y Park
Journal:  BMC Biotechnol       Date:  2011-06-02       Impact factor: 2.563

9.  Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain.

Authors:  David M Markusic; Niek P van Til; Johan K Hiralall; Ronald P J Oude Elferink; Jurgen Seppen
Journal:  BMC Biotechnol       Date:  2009-10-07       Impact factor: 2.563

10.  Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid.

Authors:  Christoph Volpers; Christian Thirion; Volker Biermann; Stefanie Hussmann; Helmut Kewes; Patrick Dunant; Helga von der Mark; Andreas Herrmann; Stefan Kochanek; Hanns Lochmüller
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.